Patel Naimish bought CRSP
March 20, 2026 · Form 4 insider transaction
Patel Naimish bought 30,000 shares of CRISPR Therapeutics AG at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 4 days after the transaction.
Footnotes
Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.; These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031.; This restricted stock unit award was granted on March 20, 2026 with respect to 30,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2027 , (ii) one quarter of the shares vesting on March 20, 2028, (iii) one quarter of the shares vesting on March 20, 2029, and (iv) one quarter of the shares vesting on March 20, 2030.